In the modified intent-to-treat population ( MEC = 634 ; HEC = 707 ) , both APF530 doses were noninferior to palonosetron in preventing acute CINV after MEC ( CRs 74.8 % [ -9.8 , 9.3 ] and 76.9 % [ -7.5 , 11.4 ] , respectively , vs. 75.0 % palonosetron ) and after HEC ( CRs 77.7 % [ -11.5 , 5.5 ] and 81.3 % [ -7.7 , 8.7 ] , respectively , vs. 80.7 % palonosetron ) .